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α-Galactosylceramide protects 
swine against influenza infection 
when administered as a vaccine 
adjuvant
Bianca L. Artiaga1,*, Guan Yang1,*, Timothy J. Hackmann1, Qinfang Liu2,†, Jürgen A. Richt2, 
Shahram Salek-Ardakani3, William L. Castleman4, John A. Lednicky5,6 & John P. Driver1
Natural killer T (NKT) -cells activated with the glycolipid ligand α-galactosylceramide (α-GalCer) 
stimulate a wide array of immune responses with many promising immunotherapeutic applications, 
including the enhancement of vaccines against infectious diseases and cancer. In the current study, 
we evaluated whether α-GalCer generates protective immunity against a swine influenza (SI) virus 
infection when applied as an intramuscular vaccine adjuvant. Immunization of newly weaned piglets 
with UV-killed pandemic H1N1 A/California/04/2009 (kCA04) SI virus and α-GalCer induced high titers 
of anti-hemagglutinin antibodies and generated virus-specific T cells that localized in intrapulmonary 
airways and in alveolar walls. Vaccination with α-GalCer resulted in a systemic increase in NKT-cell 
concentrations, including in the respiratory tract, which was associated with complete inhibition of 
viral replication in the upper and lower respiratory tract and much reduced viral shedding. These results 
indicate that NKT-cell agonists could be used to improve swine vaccine formulations in order to reduce 
the clinical signs of SI infection and limit the spread of influenza viruses amongst commercial pigs.
Swine influenza (SI) is an important infectious disease of pigs caused by influenza A viruses (IAV)1. Some of these 
are capable of causing human pandemics. For example, the 2009 pandemic H1N1 virus (H1N1pdm09) caused 
thousands of deaths, millions of hospitalizations and led to billions of dollars in lost revenue for the pork industry. 
Although swine influenza (SI) is typically caused by only three subtypes of IAV (H1N1, H1N2, and H3N2), these 
continue to evolve at an ever-increasing pace. Addressing this threat has proven very difficult because currently 
available SI vaccines fail to provide sterilizing immunity, even when closely matched to viruses in the field2–5. 
Thus, there is an urgent need to explore new solutions to improve vaccinations against IAV infections in swine. 
One promising approach is the use of natural killer T (NKT) cells that may have potential to enhance vaccine 
responses when activated using synthetic glycolipids.
Invariant NKT-cells are a minor lymphocyte subset that share phenotypic characteristics of both NK cells and 
T lymphocytes and express a semi-invariant T cell receptor (TCR) repertoire that recognizes self and foreign gly-
colipid antigens presented by the non-polymorphic CD1d molecule. Often referred to as the “Swiss Army knife” 
of the immune system for their ability to stimulate diverse immune functions6, NKT-cells promote antimicrobial 
and antitumor responses through a combination of rapid release of cytokines7, maturing dendritic cells (DCs)8, 
activating NK cells9,10 and boosting polyclonal antibody production11,12. They also induce Th1-biased cellular 
responses that optimize host immune defenses against viral pathogens13, which underlies why mice genetically 
lacking NKT-cells are more susceptible to several viral pathogens including influenza viruses14–17.
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NKT-cell agonists have been used as vaccine adjuvants in rodent models18. The glycolipid antigen most stud-
ied for this purpose is α -galactosylceramide (α -GalCer). It potently stimulates NKT-cells to release large quan-
tities of cytokines that induce the trans-activation of a wide array of bystander cells including NK cells, DCs, 
and conventional T cells subsets [reviewed in19]. These NKT-cell-mediated responses boost the efficacy of influ-
enza vaccines resulting in strong protection against lethal challenges with H1N1 or H3N2 virus strains in mouse 
models20–24. We previously investigated whether NKT-cell agonists also have potential for enhancing vaccine 
responses in swine and showed that pigs co-injected with α -GalCer and the model antigen hen-egg lysozyme 
(HEL) generate strong anti-HEL cell and antibody immune responses25.
In the current work we demonstrate the feasibility of using NKT-cell agonists to generate cellular and humoral 
immune responses to improve influenza vaccines in swine that are the natural host of SI viruses. These results 
indicate a potential veterinary use for NKT-cell adjuvants for protecting commercial swine from influenza viruses 
and other important pathogens.
Results
α-GalCer increases NKT cells in blood, lung, and lymphoid tissues. To investigate whether co-im-
munization with α -GalCer and inactivated CA04 virus protects swine from SI virus infection when injected 
into the neck muscle, where most swine vaccines are delivered, 3-week-old piglets were vaccinated with 106 
TCID50 UV-killed CA04 (kCA04) alone or with 100 μg/kg α -GalCer, or mock vaccinated with virus-free media. 
All groups contained pigs with a similar range of pre-trial NKT-cell frequencies (Table 1). Immunizations were 
repeated 16 days later, and pigs were mock inoculated or challenged intratracheally with 106 TCID50 CA04 after 
16 more days. Half of the piglets in each group were euthanized at 3 or 7 days post infection (p.i.), respectively. 
No differences were detected amongst any of the groups for body weight gain throughout the vaccination and 
challenge periods of the study (Table 1). No signs of discomfort or distress were observed for pigs injected with 
kCA04 or α -GalCer.
To assess how α -GalCer affects the expansion and distribution of NKT-cells, pig cells were analyzed by flow 
cytometry during the vaccination and challenge periods using a mouse CD1d tetramer reagent that binds the 
porcine invariant NKT-cell TCR (Fig. 1a)25. Peripheral blood NKT-cell frequencies rapidly increased between 4 
to 9 days after primary vaccination with α -GalCer and kCA04 and then decreased by day 13 (Fig. 1b). A similar 
change in NKT-cell frequencies was observed after the booster vaccination with the exception that maximum 
NKT-cell expansion occurred at day 4 (20 days after primary vaccination) rather than day 9 after α -GalCer 
co-immunization. NKT-cells remained high in α GC+ kCA04/CA04 pigs during the 7-day post inoculation 
period (Fig. 1b). NKT-cell frequencies in all the other treatment groups remained low and stable during the entire 
trial. NKT-cell subsets that are functionally distinct in other species were analyzed according to membrane bound 
CD426–28. Pigs contain few CD4+ NKT-cells in PB compared to mice and humans25. We found that α -GalCer 
administration expanded mostly the CD4− subset (Fig. 1c).
The α -GalCer vaccination protocol primed an immune response that increased NKT-cell concentrations in 
BALF, lung tissue, TBLN and spleen after challenge (Fig. 1d). No change in NKT-cell frequency was detected in 
pigs mock vaccinated or vaccinated with kCA04 alone. To determine whether other leukocyte populations were 
affected by exposure to CA04 or α -GalCer, PB and tissues were compared by flow cytometry at the same time that 
they were analyzed for NKT-cells. No differences were found amongst any groups for conventional, regulatory 
and γ δ T lymphocytes, B lymphocytes, monocytes, and granulocytes (Supplemental Fig. 2 and Supplemental 
Tables 1–4). Our observations demonstrate that α -GalCer injected into the neck muscle induces the increase of 
NKT-cells systemically, including in the respiratory tract where they were detected at high concentrations at 3 
weeks after vaccination.
Co-immunization of inactivated CA04 and α-GalCer boosts CA04-specific antibody 
responses. α -GalCer-activated NKT-cells can partially substitute for CD4+ T cell help to induce antibody 
production by B cells12,29,30. Therefore, we examined PB and BALF for SI virus-specific humoral responses during 
the course of the experiment. Prior to the start of the study all pigs were serologically negative for H1N1 SI virus 
antibodies by hemagglutination inhibition (HAI) assay. Only vaccinated pigs seroconverted to become H1N1 
positive during the vaccination period. Average titers in plasma were significantly higher for pigs co-immunized 
with α -GalCer and kCA04 than kCA04 alone (Fig. 2). The adjuvant effects of α -GalCer induced CA04-specific 
Treatment groups
Number of 
pigs
Pre-trial NKT cell 
frequency (% of CD3+ 
PB cells)
Initial body 
weight (kg)
Average daily 
gain (kg/day)
Mock/Mock 6 0.23 ± 0.11 7.59 ± 0.60 0.22 ± 0.01
Mock/CA04 8 0.17 ± 0.07 7.73 ± 0.48 0.23 ± 0.02
kCA04/CA04 7 0.23 ± 0.09 7.22 ± 0.65 0.24 ± 0.02
α GC+ kCA04/CA04 8 0.29 ± 0.19 8.00 ± 0.58 0.24 ± 0.01
Table 1.  Characteristics of experimental pigs. Data were combined from two independent experiments. 
Values represent mean ± SEM. No significant differences were detected between treatment groups for any 
of the parameters measured. Experimental groups were: Mock vaccinated and mock challenged (Group 1; 
Mock/Mock); mock vaccinated and CA04 challenged (Group 2; Mock/CA04), kCA04 vaccinated and 
CA04 challenged (Group 3; kCA04/CA04); α -GalCer+ kCA04 vaccinated and CA04 challenged (Group 4; 
α GC+ kCA04/CA04). Pre-trial NKT cell frequency was analyzed from peripheral blood (PB) at 2 weeks of age.
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antibodies from 13 days after primary vaccination with kCA04, which was 3 days before the booster vaccination. 
In contrast, CA04-specific antibodies were detected 25 days after primary vaccination in pigs that received kCA04 
alone, which was 9 days after the booster vaccination. Peak antibody titers were measured between 2 and 3 days 
p.i. for α -GalCer treated pigs compared to day 5 p.i. for pigs vaccinated with virus alone. Low antibody titers were 
detected in mock-vaccinated pigs from day 5 p.i.
To evaluate the development of protective antibody responses in the lung mucosa, BALF was analyzed for 
levels of CA04-specific anti-hemagglutinin antibodies. Only BALF from the α -GalCer treated pigs contained 
detectable antibody titers, although at levels much lower than measured in plasma because BALF was diluted 
by lavaging the left lung with 50 ml of MEM (Table 2). These collective data indicate that the adjuvanticity of 
α -GalCer enhances both systemic and mucosal concentrations of influenza-specific antibodies.
Vaccination with α-GalCer induces virus-specific cellular immunity that is variable amongst 
pigs. Combined NKT-cell activation and influenza virus vaccination is known to boost vaccine-specific T cell 
immunity20–23, in part, by potently activating professional antigen presenting cells through cytokine secretion 
and CD40-CD40L interactions. Thus, we analyzed the frequency of CA04-reactive T cells within different tissues 
by IFN-γ ELISPOT assay, which involved re-stimulating single cell suspensions with kCA04 in culture for 72 h. 
α -GalCer induced low levels of CA04-reactive PBMCs during the vaccination period that increased at 7 days post 
challenge, although there was no significant difference compared to pigs vaccinated with kCA04 alone (Fig. 3a). 
Figure 1. α-GalCer expands porcine NKT-cells that are mostly CD4−. (a) Representative flow cytometry 
plots comparing peripheral blood (PB) NKT-cells from a mock-vaccinated pig versus a pig vaccinated with 
α -GalCer. Single cell suspensions were membrane-labeled with anti-CD3 mAb and PBS57-loaded CD1d 
tetramer. Gating to discriminate CD4+ and CD4− NKT-cell subsets was based on CD4 staining after gating 
on CD3+ lymphocytes. (b) Frequency of NKT-cells as a percentage of CD3+ lymphocytes in PB of individual 
pigs during the vaccination period and post infection (shaded region). (c) Percentage of CD4− NKT-cells in PB 
during the vaccination period and post infection (shaded region). (d) Frequency of NKT-cells as a percentage 
of total lymphocytes in bronchoalveolar lavage fluid (BALF), lung, tracheobronchial lymph node (TBLN) and 
spleen at 3 and 7 days p.i. Differences in PB NKT-cell frequencies and subsets were analyzed using the SAS 
PROC MIXED procedure and the Turkey’s test was used to examine treatment differences at each time point for 
each dependent variable. Changes in BALF, lung, TBLN and spleen NKT-cell frequencies were analyzed using 
the Kruskal-Wallis test. *P < 0.05. Data are represented as mean ± SEM. Arrows indicate when vaccinations 
were administered.
www.nature.com/scientificreports/
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α -GalCer-vaccinated pigs tended to have higher concentrations of CA04-reactive cells in spleen at 7 days p.i. 
and in lung at 3 and 7 days p.i. compared to pigs vaccinated with kCA04 alone (Fig. 3b). There was no statistical 
difference between groups for spleen and lung due to the large range of NKT-cell concentrations amongst the pigs 
enrolled in the α -GalCer treatment group, which may have contributed to the highly variable T cell responses to 
NKT-cell activation that we observed. Indeed, concentrations of CA04-reactive PBMCs were tightly correlated 
to the frequency of peripheral NKT-cells in pigs vaccinated with α -GalCer (r2 = 0.81, p-value = 0.02) (Fig 3c; left 
panel). No correlations were found between NKT cells and CA04-reactive PBMCs for pigs that were vaccinated 
with kCA04 alone (data not shown). Collectively, these data suggests that a certain threshold level of NKT-cells is 
needed for α -GalCer to induce effective virus-specific cellular immunity. In contrast, no correlation was detected 
between NKT-cell concentrations and anti-hemagglutinin antibody titers (r2 = 0.08, p-value = 0.49) (Fig 3c; right 
panel), indicating that NKT-cell-mediated humoral immunity may not depend on whether pigs contain high or 
low levels of NKT-cells.
Localization of CD3+ T cells after SI virus infection. Lung tissue was examined by immunohistochem-
istry to evaluate the effects of vaccination and infection on T cell recruitment and distribution in the respiratory 
tract. Virus infection induced localization of CD3+ T cells in bronchial, bronchiolar and alveolar walls. CD3+ 
T cells were most densely localized in bronchiolar walls of virus-inoculated pigs. In Mock/Mock pigs, only rare 
CD3+ cells were visualized in the lamina propria of bronchioles (Fig. 4A–C). Virus inoculation alone (Mock/
CA04) resulted in low-density infiltrates of CD3+ cells multifocally in bronchiolar walls at 3 days p.i. (Fig. 4D–F). 
In contrast, in both groups of vaccinated pigs (with and without α -GalCer), high numbers of CD3+ cells could be 
readily visualized around bronchioles in lamina propria and adventitia. Few intra-epithelial CD3+ cells were seen 
in the vaccinated and challenged group (kCA04/CA04) (Fig. 4G–I). Pigs receiving α -GalCer (α GC+ kCA04/
CA04) had higher density of intra-epithelial CD3+ cells associated with hyperplastic bronchiolar epithelium than 
did vaccinated pigs that did not receive α -GalCer (Fig. 4G–I versus Fig 4J–L). High-density CD3+ T cell infil-
trates were present in bronchioles from pigs in both vaccinated groups at 7 days after virus inoculation com-
pared to low density CD3+ cells in pigs at 7 days that only received virus (data not shown). Again, pigs receiving 
α -GalCer appeared to have higher density of CD3+ cells in their bronchiolar walls at 7 days than did vaccinated 
pigs that did not receive α -GalCer (data not shown).
Immunization with inactivated CA04 and α-GalCer reduces virus in lung and nasal secre-
tions compared to inactivated CA04 alone. Nasal swab virus titers were considerably reduced in 
CA04-challenged pigs immunized with kCA04 and α -GalCer (α GC+ kCA04/CA04) compared to pigs that were 
Figure 2. Geometric mean of HAI titers against CA04 H1N1 antigen in plasma at during the 32 day 
vaccination period as well as 2, 3, 5 and 7 days post-infection (indicated by the shaded region). Arrows 
indicate when vaccinations were administered. Geometric mean was calculated as the ‘n’th root product of ‘n’ 
numbers.
Treatment groups 3 days p.i. 7 days p.i.
Mock/Mock < 10 < 10
Mock/CA04 < 10 < 10
kCA04/CA04 < 10 20
α GC+ kCA04/CA04 28.3 33.6
Table 2.  Geometric mean HAI titers against CA04 H1N1 in broncho-alveolar lavage fluid (BALF) at 
3 and 7 days post-infection. Experimental groups were: Mock vaccinated and mock challenged (Group 1; 
Mock/Mock); mock vaccinated and CA04 challenged (Group 2; Mock/CA04), kCA04 vaccinated and 
CA04 challenged (Group 3; kCA04/CA04); α -GalCer+ kCA04 vaccinated and CA04 challenged (Group 4; 
α GC+ kCA04/CA04). Geometric mean was calculated as the ‘n’th root product of ‘n’ numbers.
www.nature.com/scientificreports/
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Figure 3. Cellular responses to CA04 H1N1 antigen were measured by IFN-γ-ELISPOT assays. IFN-γ 
production by CA04-reactive cells in (a) PBMCs during the vaccination period and post infection (shaded 
region) and (b) spleen and lung at 3 and 7 days p.i. Single cell suspensions were incubated for 72 h with 
UV-inactivated CA04 H1N1 virus. Results represent mean IFN-γ spots per 104 leukocytes after subtracting 
spots counted in unstimulated wells. Results are displayed as the mean ± SEM. Means were compared using 
the Kruskal-Wallis test. *P < 0.05. (c) Correlations between peripheral blood NKT-cell frequencies and 
concentrations of CA04-reactive cells in PBMCs (left panel) and CA04-specific antibody titers in plasma (right 
panel) at day 29 after primary vaccination. Correlations were determined using linear regression analysis and 
the line in each plot represents the best linear fit.
www.nature.com/scientificreports/
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vaccinated with kCA04 alone (kCA04/CA04), although the differences were not statistically significant on days 3 
and 5 p.i. (Fig. 5a). Most strikingly, virus titers were very low (≤ 103 TCID50 units/ml) in α GC+ kCA04/CA04 pigs 
at all time points after inoculation. Vaccination with kCA04 alone (kCA04/CA04) only partially reduced virus 
titers compared to mock vaccinated and CA04 challenged pigs (Mock/CA04), and only on days 3 and 5 p.i. These 
collective results show that α -GalCer can significantly decrease virus shedding from nasal fluids when adminis-
tered with inactivated whole virus compared to pigs immunized with whole virus alone.
Virus titers were also measured in upper and lower airway tissues to determine the effect of the α -GalCer 
vaccination protocol on viral replication at different locations within the respiratory tract. Virus was undetectable 
in trachea and bronchus as well as throughout the lung of all α GC+ kCA04/CA04 pigs at both 3 and 7 days p.i. 
However, virus titers were only partially reduced in kCA04/CA04 pigs at 3 days p.i. compared to Mock/CA04 
pigs, which represents a time point when high levels of viral replication occurs in the CA04 challenge model 
(Fig. 5b).
Consistent with the viral titer results, histopathology performed using a polyclonal antibody against IAV 
antigen detected diffuse bronchiolar epithelial localization of virus antigen in Mock/CA04 pigs (Fig. 6B & 
Supplemental Table 5). There was also virus antigen multifocally in type II alveolar epithelial cells in areas of 
Figure 4. Localization of CD3+ T cells after SI virus infection. Mock/Mock: Images (A–C). Images (A,B) are 
transverse and longitudinal sections of CD3 stained bronchioles at 180× magnification. Image (C) is at 360× . 
Mock/CA04: Images (D–F). Images (D,E) are transverse and longitudinal sections of CD3 stained bronchioles 
at 180× with low density CD3+ T-cells in bronchiolar walls. Image (F) is at 360× showing dark brown, CD3-
stained T-cells in bronchiolar walls. kCA04/CA04: Images (G–I). Images (G,H) are transverse and longitudinal 
sections of CD3 stained bronchioles at 180× with thickened bronchiolar walls containing moderate to high 
density aggregates of CD3+ T-cells. Image (I) is at 360× showing high density CD3+ cells in the bronchiolar 
wall below columnar to cuboidal bronchiolar epithelial cells. α GC+ kCA04/CA04: Images (J–L). Images 
(J,K) are transverse and longitudinal sections of CD3 stained bronchioles at 180× with markedly thickened 
bronchiolar walls containing moderate to high density aggregates of CD3+ T-cells with infiltration of CD3+ 
T-cells within bronchiolar epithelium which is hyperplastic. Image (L) is at 360× showing high density CD3+ 
cells in the bronchiolar wall within hyperplastic cuboidal bronchiolar epithelial cells.
www.nature.com/scientificreports/
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mild interstitial pneumonia surrounding terminal bronchioles. For kCA04/CA04 pigs, multifocal virus antigen 
was detected in epithelial cells and in type II alveolar epithelial cells in surrounding areas of mild pneumonia 
(Fig. 6C). In contrast, pigs in the α GC+ kCA04/CA04 and Mock/Mock treatment groups did not have detecta-
ble virus antigen in bronchiolar epithelial cells or in surrounding type II alveolar epithelial cells (Fig. 6A,D). In 
addition, they also did not have detectable virus antigen in bronchi. Collectively, these results indicate that using 
α -GalCer as a vaccine adjuvant in combination with kCA04 elicits immunity that effectively inhibits viral repli-
cation and shedding.
Discussion
In the current study, we demonstrate that α -GalCer co-immunized with inactivated CA04 into the neck muscle of 
piglets generated protective immunity against homologous influenza infection, indicating that NKT-cell agonists 
could be used to improve swine vaccine formulations in order to reduce the clinical signs of SI infection and limit 
the spread of influenza viruses among commercial pigs.
Current commercially available SI vaccines are mostly traditional inactivated whole viruses containing multi-
valent mixtures of H1 variants and an H3 SI virus subtypes. A major drawback of this approach is that inactivated 
virus vaccines fail to provide consistent sterilizing immunity that blocks infection, even in years when the vaccine 
Figure 5. Viral titers in mock-vaccinated pigs (Mock) and pigs intramuscularly vaccinated 2 times with 
inactivated CA04 H1N1 virus (kCA04) alone or with α-GalCer (αGC) that were mock inoculated or 
challenged with homologous CA04 virus. Mean virus titers for (a) nasal swabs at 1, 2, 3, 5, and 7 days p.i. and 
(b) homogenized airway tissues at 3 and 7 days p.i. Changes in nasal swab titers were analyzed using the SAS 
PROC MIXED procedure and the Turkey’s test was used to examine treatment differences at each time point for 
each dependent variable. Changes in tissue titers were analyzed using the Kruskal-Wallis test. *P < 0.05. Data 
are represented as mean ± SEM.
www.nature.com/scientificreports/
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is a good match for circulating viruses31. Therefore, research is needed to improve vaccinations for reducing the 
threat of seasonal and pandemic influenza outbreaks in swine.
Harnessing NKT-cells could be an effective approach to improve inactivated whole-virus vaccines because of 
their unique ability to kick-start both innate and adaptive immune responses in ways that generate large quanti-
ties of antigen-specific antibodies and T cells32. NKT-cells share many functions with conventional CD4+ T helper 
cells, including that they license DCs8, cross-prime CD8+ T cells22 and stimulate antibody isotype switching 
and affinity maturation by B cells12,29,30, which are all important requirements for generating effective protective 
immunity. However, while the CD4+ T cell compartment is comprised of millions of clonotypes that recognize 
different peptide antigens in an MHC-restricted fashion, NKT-cells interact with the non-polymorphic CD1d 
molecule and a limited range of glycolipid antigens. This offers the advantage that NKT-cells can be generi-
cally activated using synthetic glycolipids for a variety of therapeutic applications. Rodent studies have already 
demonstrated the potential of NKT-cell agonists as adjuvants for vaccines against influenza20–24. The current study 
extends these findings to swine that are an important agricultural species, which are heavily affected by influenza 
infections and that are capable of transmitting zoonotic influenza strains to humans33.
Consistent with what has been reported for mice21–24, we found that vaccinating pigs with α -GalCer and 
inactivated virus induced immune responses that inhibited viral replication and shedding more effectively than 
vaccinating pigs with inactivated virus alone. The protective effect of α -GalCer was associated with increased 
concentrations of anti-hemagglutinin antibodies and a tendency for higher cellular responses against viral anti-
gens. We postulate that the CA04-specific antibodies were most important during early infection for preventing 
virus particles from entering airway epithelial cells, while cells that did become infected may have been elimi-
nated by cellular responses during the latter stages of disease. It is currently unknown whether the accumulation 
of  T cells at the intra-epithelial interface between the bronchiolar wall and lumen is important for why viral rep-
lication was completely blocked in the α -GalCer vaccinated pigs. It is difficult to assess how much virus clearance 
was due to T cell-mediated immune responses in the current study. However, it has been shown that α -GalCer 
co-administration with inactivated IAV promotes the survival of long-term memory cytotoxic T lymphocyte 
populations capable of boosting cross-protection against heterozygous IAV challenge22. Demonstrating the same 
phenomenon in pigs would be highly relevant for vaccine producers because of the large number of influenza 
viruses circulating in the field that are constantly changing. Surprisingly, although NKT-cell frequencies in ani-
mals receiving α -GalCer varied by more than 200 fold, there was no correlation between systemic NKT-cell 
concentration and antibody responses in individual pigs. This finding suggests that α -GalCer-mediated humoral 
immunity depends more on functional subtypes of NKT-cells or the immune cells they transactivate rather than 
the number of NKT-cells per se a pig possesses. In contrast, antigen-specific cellular responses were much more 
Figure 6. Localization of viral antigen in lung at 3 days post infection. All images are transverse sections 
of bronchioles and alveolar tissue stained for H1N1 antigen at 174x magnification. Mock/Mock: Image (A). 
Bronchioles and alveolar tissue are negative for H1N1 antigen. Mock/CA04: Image (B). There is diffuse staining 
of H1N1 antigen in bronchiolar epithelium (large arrowheads). Type II alveolar epithelial cells stain multifocally 
(small arrows). kCA04/CA04: Image (C). There is multifocal staining of H1N1 antigen in bronchiolar epithelial 
cells (large arrowheads). Type II alveolar epithelial cells stain multifocally (small arrows). α GC+ kCA04/CA04: 
Image (D). Bronchioles and alveolar tissue are negative for H1N1 antigen.
www.nature.com/scientificreports/
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correlated to NKT-cell frequency, which is significant because of the importance of T cells for generating long 
lasting memory and cross-protection against virus infections.
Another similarity to mouse studies was that vaccination with α -GalCer caused an increase of porcine 
NKT-cells both systemically and within airway tissues. It is possible that some protective immunity provided by 
the α -GalCer vaccination protocol was partially due to NKT-cells present in lung tissues reducing viral replica-
tion through stimulating a variety of early innate immune responses. However, α -GalCer does not protect mice 
from influenza infections, unless the agonist is co-administered with influenza virus before infection23,24. This 
indicates that enhanced adaptive immune responses are likely to be the main reason why α -GalCer+ kCA04 vac-
cinated pigs were better protected compared to pigs that received kCA04 alone. In future, it will be important to 
treat pigs with α -GalCer alone to definitely address whether NKT-cells confer protection through innate immune 
mechanisms and/or by stimulating the adaptive immune system.
Our observation that α -GalCer expanded mostly the CD4− subset of NKT-cells may be significant for how 
swine were protected against disease, because in mice and humans CD4− NKT-cells are highly cytolytic and pro-
duce Th1-cytokines34, which are important for lysing virus-infected cells. In contrast, the CD4+ subset produces 
both Th1 and Th2 cytokines and has often been associated with tolerogenic activity35–37. However, it remains to be 
determined whether NKT-cell subsets in pigs are functionally equivalent to those in other species.
In conclusion, our study is the first to demonstrate the adjuvanticity of α -GalCer for enhancing inactivated 
influenza vaccines in pigs. Intramuscular administration of α -GalCer in combination with inactivated virus gen-
erated protective immune responses against viral replication within airway tissue, which is of practical impor-
tance because most swine vaccines are injected into the neck muscles. The effects of NKT-cell activation we 
observed in pigs closely mirrors what occurs in mice immunized with α -GalCer and challenged with homolo-
gous virus20–24. This provides encouragement that NKT-cell agonists can also be used for pigs, as they have been 
for mice, to increase the protective immunity of inactivated whole-virus influenza vaccinations against SI virus 
infections. Future studies should address whether vaccinating pigs with α -GalCer is capable of enhancing more 
long-lasting immunity compared to other vaccine adjuvants to be of relevance for commercial pig production. 
Encouragingly, it has been reported that mice immunized with a single administration of inactivated IAV and 
α -GalCer were completely protected against a lethal dose of influenza virus infection that lasted for at least 3 
months23. Experiments should also be performed to establish whether intranasal delivery of α -GalCer induces 
immune responses in mucosal tissues that can improve the cross-protection of influenza vaccines.
Methods
Pigs. Piglets were farrowed from sows that are a mixture of Yorkshire, Chester White, Duroc, Hampshire, and 
Landrace breeds, which are maintained at the University of Florida’s swine unit. Breeding of sows is performed 
by artificial insemination using semen collected on-site or from Swine Genetics International (SGI) (Cambridge, 
IA), Top Cut Genetics (Farmland, IN) or Shaffer’s Goldrush (Albany, IN). Experiments were carried out in 
accordance with approved guidelines from the United States Department of Agriculture, the National Research 
Council’s Guide for the Care and Use of Laboratory Animals, as well as all relevant state and federal regulations 
and policies. The animal care and use committee at the University of Florida approved all experimental protocols 
under the project number 201308209. Prior to first use, the animals were confirmed free of antibodies to CA04 
using hemagglutination inhibition (HAI) assays, and were also checked for the presence of antibodies to influenza 
H3N2 and B viruses.
Virus and vaccine preparation. Influenza virus encoding the original consensus sequence of the 
H1N1pdm09 strain A/California/04/2009 (CA04) was generated by reverse genetics (RG) using plasmids with 
cloned cDNA encoding all H1N1 viral genes as previously described38. Viable virus was recovered in a combina-
tion of 293T (human embryonic kidney cells expressing SV40 large tumor antigen) and MDCK (Madin Darby 
Canine Kidney) cells essentially as described previously38, using lipofectamine 2000 (ThermoFisher Scientific, 
Grand Island, NY) as the transfection agent. The 293T and MDCK were propagated using standard conditions in 
cell growth media containing low immunoglobulin (Ig) G, heat-inactivated gamma-irradiated fetal bovine serum 
(FBS) (HyClone Laboratories Inc., Logan, UT). Prior to use, the cells were treated for 3 weeks with plasmocin and 
verified free of mycoplasma DNA by PCR39.
Virus produced from the RG system was subsequently propagated once in MDCK cells incubated at 33 °C, 
and the virus produced authenticated as CA04 by sequencing of the hemagglutinin and neuraminidase genes. 
For all virus work, the MDCK cells were in serum-free complete Advanced Dulbecco’s Modified Eagle’s Medium 
(aDMEM) (ThermoFisher Scientific). The aDMEM was supplemented with 2 mM L-Alanyl-L-Glutamine 
(GlutaMAX, ThermoFisher Scientific), antibiotics (PSN; 50 μg/mL penicillin, 50 μg/mL streptomycin, 100 μg/mL 
neomycin) (ThermoFisher Scientific) containing 2.0 μg/ml L-1-tosylamide-2-phenylethyl chloromethyl ketone 
(TPCK)-treated trypsin, mycoplasma- and extraneous virus-free trypsin (Worthington Biochemical Company, 
Lakewood, NJ).
Virus titers were calculated from the median (50%) tissue culture infectious dose (TCID50), and viral titers 
expressed as TCID50/ml, TCID50/g, or their Log10-transformed values, as appropriate40,41. Briefly, the TCID50 
values were determined by infecting MDCK cells in 96-well microtiter plates with serial dilutions of virus and 
calculation of the TCID50 five days later by the method of Reed and Muench42. To produce vaccines, virus parti-
cles were suspended in serum-free aDMEM and were UV-inactivated by placing 20 ml aliquots of virus at titers 
of approximately 3 × 107 TCID50/ml in plastic petri dishes and irradiating open dishes in a biosafety cabinet for 
30 minutes. Inactivation of each batch of virus was verified using viability checks with 1/20 of each irradiated sam-
ple; lack of cytopathic effects in MDCK cells in serum-free media with TPCK-trypsin after 1 week of incubation 
at 33 °C was accepted as proof of complete inactivation of the virus.
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Preparation of α-GalCer. α -Galactosylceramide was purchased from Avanti Polar Lipids, Inc. (Alabaster, 
AL) and sonicated in DMSO at 2 mg/ml until fully dissolved. α -GalCer stock solutions were further dissolved in 
PBS in combination with inactivated virus for administration to pigs.
Experimental design for vaccination and challenge. Two-week-old piglets were bled from the jug-
ular vein to determine their NKT-cell frequencies in peripheral blood (PB). Twenty-nine piglets were selected 
and assigned to one of four individual treatments so that each group contained animals with a similar range of 
NKT-cell frequencies (Table 1). Four days before vaccination, piglets were transferred to isolation rooms. All 
piglets were seronegative for H1N1 SI viruses in HAI assays. At 3 weeks of age (−32 days post-infection [p.i.]) 
and 5 weeks of age (−16 days p.i.), pigs in groups 1 and 2 were mock vaccinated intramuscularly (i.m.) with 2 ml 
of serum-free MEM while those in groups 3 and 4 were respectively injected with 106 TCID50 UV-killed CA04 
(kCA04) virus alone or in combination with 100 μg/kg of α -GalCer. During the 32 day vaccination period, pigs 
were bled at the indicated time points to characterize immune cells subsets, including NKT-cell frequencies, and 
CA04-specific antibody and cellular responses. Sixteen days after the second vaccination (0 days p.i.), pigs in 
group 1 were mock inoculated intratracheally with virus-free MEM while groups 2 to 4 were inoculated with 106 
TCID50 CA04 (Table 1). Before inoculation, the animals were sedated with a combination of ketamine (2.2 mg/
kg)/xylazine (2.2 mg/kg)/telazol (4.4 mg/kg), administered at a rate of 1 ml/50 lbs of body weight. Virus was deliv-
ered using a catheter that was passed through a laryngoscope into the trachea. The intratracheal route of inocula-
tion was selected to assure a consistent level of infection. During the 7 day p.i. period, pigs were monitored daily 
for disease symptoms such as coughing, nasal and ocular discharge, and weight loss. Blood samples were collected 
at 2, 5 and 7 days p.i. to measure CA04-specific antibody and cellular responses as well as for analysis of immune 
cell populations by flow cytometry.
Nasal swabs were collected on 1, 2, 3, 5 and 7 days p.i to measure virus titers. Nasal secretions were collected 
using sterile flocked swabs (Copan Diagnostics, Inc., Murrieta, CA), and the swabs immersed immediately after-
wards in 1 ml of Copan Virus Transport Medium (VTM) in a transport tube. The swab specimens were then 
frozen at − 80 °C until the virus therein was titered on MDCK cells. Antibiotics (penicillin, neomycin, and strep-
tomycin) to control bacteria and fungizone (amphotericin B, from Invitrogen) to control fungi and yeast, was 
added to the cell-growth media. For virus titrations, the VTM tubes were thawed on ice, then the swabs twirled 
against the inside surfaces of the tube to extrude collected material into the VTM. The virus titer/ml was obtained, 
and the value expressed as TCID50/swab.
Pigs were euthanized at 3 or 7 days p.i. for necropsy and tissue collection. Euthanasia was accomplished 
by injecting pigs with 150 mg/kg Pentobarbital Sodium IV through the auricular vein, after pigs were sedated 
with a combination of ketamine/xylazine/telazol. Death was confirmed by auscultation for lack of heartbeat. 
Immediately after euthanasia, the axillary vessels in the front legs were severed to exsanguinate the carcass to 
avoid blood pooling in the lungs. Necropsy was performed by a board-certified veterinary pathologist (WLC). 
Trachea was bisected and cannulated for fixation of trachea, bronchi and right middle, right caudal and right 
accessory lung lobes. The left lung was separated at the left main stem bronchus. Fresh samples were aseptically 
collected from trachea, left bronchus and left lung lobes for analysis of virus titers. Tissue samples were also 
collected from left lung lobes, right cranial lung lobe, spleen and tracheobronchial lymph nodes (TBLN) for ana-
lyzing immune cell populations and CA04-specific cellular responses. Bronchoalveolar lavage fluid (BALF) was 
collected at necropsy by lavaging the left lung with 50 ml of MEM for examination of immune cell populations as 
well as viral titers. Results represent the combination of two independent animal studies.
For virus assays, the tissues were weighed and ~0.5 g homogenized in sterile PBS with antibiotics and 0.5% 
(w/v) purified BSA fraction V to form a 10% (w/v) homogenized suspension using sterile tissue grinders. The 
homogenates were then titrated and seeded onto confluent MDCK cells that were incubated for five days at 33 °C, 
and the titer expressed as TCID50/g tissue. The lower detection limit was estimated at 20 TCID50/g tissue.
Isolation of leukocytes from blood, spleen, lymph nodes, lung and BALF. Blood samples were 
collected from the jugular vein in vacutainer plasma tubes coated with sodium heparin (BD Biosciences, San 
Jose, CA). Isolation of peripheral blood mononuclear cells (PBMCs) was performed using standard procedures 
with Ficoll-PaqueTM PREMIUM (GE Healthcare BioSciences Corp., Uppsala, Sweden) as previously described25. 
Spleen and lymph node tissues were collected and dispersed into single cell suspensions using closed sterile 
tissue grinders as previously described25. Lung tissues were minced using scissors, digested with a mixture of 
2 U/ml DNase I (Zymo Research, Irvine, CA) and 250 U/ml collagenase type III (Worthington Biochemical, 
Worthington, NJ) at 37 °C for 45 minutes and filtered through a 100 μm cell strainer. BALF was filtered using a 
100 μm cell strainer. An ammonium chloride-based lysis buffer was used to remove residual red blood cells from 
blood and tissue samples.
Flow cytometry and antibodies. Immune cell populations in blood, BALF and tissues were character-
ized using a BD Accuri C6 flow cytometer as previously described43. Briefly, single cell suspensions were treated 
with rat IgG from Sigma-Aldrich (Saint Louis, MO) to block non-specific antibody binding and stained with the 
indicated fluorochrome-conjugated antibodies at 4 °C for 30 minutes. NKT-cell frequency and subsets were char-
acterized by staining samples with the α -GalCer analog PBS57-loaded mouse CD1d (mCD1d) tetramer reagent 
or unloaded tetramer provided by the National Institutes of Health Tetramer Core Facility, as well as anti-CD3ε 
(BB23-8E6-8C8; BD Biosciences, San Jose, CA), and anti-CD4 (74-12-4; Southern Biotech, Birmingham, AL). 
NKT cells were identified as CD1d tetramer positive cells after gating on single, live, lymphocyte sized CD3+ 
cells. NKT cell subsets were defined according to presence of CD4 as gated on total CD3 positive cells. To assess 
conventional α β T cells, γ δ T cells, B cells, monocytes and granulocytes, single cell suspensions were stained with 
antibodies specific for the immune cell surface molecules CD4, CD8 (76-2-11; BD Biosciences), T cell receptor 
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δ (PGBL22A; Kingfisher Biotech, Saint Paul, MN), CD3, CD79α (HM47; BD Biosciences) and CD172α (74-22-
15A; BD Biosciences) [43 and Supplemental Fig. 1]. For intracellular FoxP3 staining, cells were surface stained 
using antibodies for CD4 and CD3 molecules before they were fixed and permeabilized with solutions contained 
within the eBiosciences FoxP3 staining set (eBiosciences, Inc., San Diego, CA). The recommended manufacturer 
staining protocol was followed using an anti-mouse/rat FoxP3 antibody (FJK-16s) (Supplemental Fig. 1). Samples 
collected after SI virus challenge were fixed according to BD the Cytofix/Cytoperm kit from BD Biosciences. Data 
were analyzed using FlowJo software (Treestar, Palo Alto, CA).
Serological and mucosal antibody assays. HAI assays were performed essentially as described44 using 
washed 0.5% turkey red blood cells (RBC). Briefly, after serum samples were treated overnight with receptor 
destroying enzyme (RDE) (Denka Seiken USA, Inc., Campbell, CA) at 37 °C to destroy nonspecific inhibitors 
of hemagglutination, the sera were heat-treated at 56 °C for 60 min to inactivate remaining RDE activity. They 
were subsequently treated with a 20% kaolin (Sigma-Aldrich, St. Louis, MO) suspension, and adsorbed with 
0.5% turkey red blood cells to remove nonspecific agglutinins. The HAI assays were performed thereafter with 4 
hemagglutination units of CA04. The first dilution was 1:10, and 1:2 thereafter.
IFN-γ enzyme-linked immunosorbent spot assays. The frequencies of CA04-reactive T lympho-
cytes in PBMC, spleen, lung, and TBLN were quantified using an IFN-γ enzyme-linked immunosorbent spot 
(ELISPOT) assay as described before25. Single cells were suspended in culture medium (RPMI 1640 containing 
10% fetal bovine serum and 1% Penicillin/Streptomycin solution) and plated in triplicate at 5 × 105 cells per 
well into MultiScreen HTS plates (Millipore, Billerica, MA) pre-coated with purified anti-IFN-γ (P2G10, BD 
Biosciences). Cells were incubated for 3 days at 37 °C with 0 (unstimulated) and 5 × 105 TCID50 kCA04 virus par-
ticles. After development, spots were read using an automated ELISPOT reader (AID EliSpot High- Resolution 
Reader System ELHR03). Data are presented as mean number of spots ± SEM/104 leukocytes after subtracting 
spots counted in unstimulated wells. The mean IFN-γ spots per 104 leukocytes for unstimulated wells were 1.1 for 
blood, 3.3 for spleen and 0.5 for lung. The number of leukocytes in each well was determined by analyzing each 
tissue sample by flow cytometry before single cell suspensions were plated. Total live leukocytes were determined 
based on forward and side scatter and propiduim iodide straining.
Immunohistochemistry. Right middle and caudal lung lobes that were fixed by intratracheal perfusion at 
30 cm H20 pressure with 10% neutral phosphate-buffered formalin for 18–24 hours were blocked out for histo-
pathology and immunohistochemistry. Blocked lung sections were taken from the proximal lobar bronchus, two 
intermediate level blocks in ventral or ventrocaudal directions. An additional section from ventral and caudal 
most peripheries was collected for a total of 8 lung sections per pig. Trachea was fixed in formalin. Tissues were 
dehydrated through alcohol series, cleared in xylene and embedded in paraffin. Paraffin sections were stained 
with hematoxylin and eosin for histopathologic analysis. Additional paraffin sections for H1N1 antigen or CD3 
immunohistochemistry were mounted on charged slides, de-paraffinized and rehydrated prior to heat-induced 
epitope retrieval in Tris-EDTA, pH 9 at 95 °C for 40 minutes (CD3) or 20 minutes (H1N1 antigen). Endogenous 
peroxidase activity was quenched by treatment with 0.3% H2O2 in methanol for 30 minutes. Nonspecific staining 
was suppressed with Background Punisher (Biocare Medical, Concord, CA) according to the manufacturer pro-
tocol. For CD3, sections were treated with rabbit anti-human CD3 (A0452, Dako, Glostrup, Denmark) at 1:100. 
Mach 4 polymer detection system with horseradish peroxidase (Biocare Medical) was used as described by the 
manufacturer. Peroxidase activity was detected with Metal Enhanced DAB (3,3′ -diaminobenzidine) Substrate 
Working Solution (Thermo Scientific, Rockford, IL) as described in the kit. For H1N1 antigen detection after 
epitope retrieval and peroxidase quenching steps, sections were treated with horse blocking serum prior to incu-
bation with goat anti-H1N1 (AB1074, Millipore, Billerica, MA) at 1:500. Bound antibody was detected with an 
ImmPRESS anti-goat IgG-polymer detection kit (MP-7405, Vector Laboratories, Burlingame, CA) prior to per-
oxidase activity detection. Slides were lightly stained with Harris hematoxylin.
Statistical analysis. For NKT-cell frequencies and nasal swab titers, data were analyzed as repeated meas-
ures using PROC MIXED of SAS (v9.3, SAS Institute Inc., Cary, NC). The model used was
µ τ τ τ= + + + + + +y t t x p e( ) ( ) (1)ijkl i j ij k il ijkl
where yijkl = the observation, μ = overall mean, τi = fixed effect of treatment i, tj = fixed effect of time j, (τt)ij = the 
interaction between treatment and time, xk = the random effect of experiment k, p(τ)il = the random effect of 
pig l within treatment, and eijkl = residual error. Either Toeplitz or spatial power structures were chosen, owing 
to values of Akaike information criterion (AIC) and the unequal spacing of measurements. Data were log trans-
formed in order to address the heteroscedasticity and non-normally distributed residuals of untransformed data. 
When the F-test for a main effect or interaction was significant (P < 0.05), multiple comparisons were done using 
Tukey’s test.
For other variables, data were analyzed using a Kruskal-Wallis test in SAS using PROC NPAR1WAY and a 
macro described by Elliot and Hynan45. For these variables, residuals were non-normally distributed even after 
transformation, necessitating the non-parametric test be used. Multiple comparisons were done using Nemenyi’s 
or Dunn’s test.
Linear regression analyses were preformed using GraphPad Prizm, version 6.0g for Macintosh (GraphPad 
Software, Inc., La Jolla, CA).
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